We therefore sought to examine the patterns of response and progression to targeted therapy by measuring every metastasis ≥5 mm via computed tomography (CT) in a cohort of patients with metastatic melanoma treated with combined BRAF and MEK inhibitors. This evidence concerns the gene MAP2K7 and metastatic melanoma.